false
0001514183
0001514183
2025-06-27
2025-06-27
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 OR 15(d) of The Securities Exchange Act of 1934
Date
of Report (Date of earliest event reported): June 27, 2025
Silo
Pharma, Inc.
(Exact
name of registrant as specified in its charter)
| Nevada |
|
001-41512 |
|
27-3046338 |
(State
or other jurisdiction
of incorporation) |
|
(Commission
File Number) |
|
(IRS
Employer
Identification No.) |
677
N. Washington Boulevard
Sarasota,
FL |
|
34236 |
| (Address
of principal executive offices) |
|
(Zip
Code) |
Registrant’s
telephone number, including area code: (718) 400-9031
N/A
(Former
name or former address, if changed since last report)
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under
any of the following provisions (see General Instruction A.2. below):
| ☐ |
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| ☐ |
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| ☐ |
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| ☐ |
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities
registered pursuant to Rule 12(b) of the Act:
| Title
of each class |
|
Trading
Symbol(s) |
|
Name
of exchange on which registered |
| Common
Stock, par value $0.0001 per share |
|
SILO |
|
The
Nasdaq Stock Market LLC |
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company ☐
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item
3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.
On
June 27, 2025, Silo Pharma, Inc. (the “Company”) was notified (the “Notification Letter”) by The Nasdaq Stock
Market, LLC (“Nasdaq”) that it is not in compliance with the minimum bid price requirements set forth in Nasdaq Listing Rule
5550(a)(2) for continued listing on The Nasdaq Capital Market. Nasdaq Listing Rule 5550(a)(2) requires listed securities to maintain
a minimum bid price of $1.00 per share, and Nasdaq Listing Rule 5810(c)(3)(A) provides that a failure to meet the minimum bid price requirement
exists if the deficiency continues for a period of 30 consecutive business days. Based on the closing bid price of the Company’s
common stock from May 14, 2025 to June 26, 2025, the Company no longer meets this requirement. The Notification Letter has no immediate
effect on the listing or trading of the Company’s common stock on The Nasdaq Capital Market and, at this time, the common stock
will continue to trade on The Nasdaq Capital Market under the symbol “Silo.”
The
Notification Letter provides that the Company has 180 calendar days, or until December 24, 2025, to regain compliance with Nasdaq
Listing Rule 5550(a)(2). To regain compliance, the bid price of the Company’s common stock must have a closing bid price of at
least $1.00 per share for a minimum of 10 consecutive business days. If the Company does not regain compliance by December 24,
2025, an additional 180 days may be granted to regain compliance, so long as the Company meets The Nasdaq Capital Market continued
listing requirement for market value of publicly-held shares and all other initial listing standards for The Nasdaq Capital Market,
other than the minimum closing bid price requirement and notifies Nasdaq in writing of its intention to cure the deficiency during
the second compliance period, by effecting a reverse stock split, if necessary. If the Company does not qualify for the second
compliance period or fails to regain compliance during the second 180-day period, then Nasdaq will notify the Company of its
determination to delist the Company’s common stock, at which point the Company will have an opportunity to appeal the
delisting determination to a Hearings Panel.
The
Company intends to monitor the closing bid price of its common stock and may, if appropriate, consider implementing available options,
including, but not limited to, implementing a reverse stock split of its outstanding securities, to regain compliance with the minimum
bid price requirement under the Nasdaq Listing Rules.
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
| |
SILO
PHARMA, INC. |
| |
|
|
| Date:
July 3, 2025 |
By: |
/s/
Eric Weisblum |
| |
|
Eric
Weisblum |
| |
|
Chief
Executive Officer |
2
